Introduction
Characterized by two or more fused aromatic rings (Ravindra et al. 2008) , PAHs are produced through pyrogenic (combustion derived), petrogenic (petroleum derived) and biogenic processes, and can include a variety of heteroatomic substitutions on or within the ring system. Non-occupational human exposure primarily occurs through the diet, especially ingestion of smoked and grilled meats and vegetables (Bansal and Kim 2015) , through direct or secondhand inhalation of tobacco smoke (Ramos and Moorthy 2005; Rodgman et al. 2000) , inhalation of polluted air, or through contact with contaminated soils and water (Goldman et al. 2001; Lundstedt et al. 2007) . Common sources of PAHs in the environment include anthropogenic activity such as petroleum and plant-based fuel use, and natural sources such as oil seeps, forest fires, and volcanic emissions (Li et al. 2002; Zhang and Tao 2009) .Such as the parent compounds, polar PAH derivatives can form directly through incomplete combustion. However, PAH derivatives can also be formed through a variety of abiotic and biotic processes, including reactions with NO x , O 3 , and OH radicals in the atmosphere (Cochran et al. 2016; Jariyasopit et al. 2014a, b; Lundstedt et al. 2007) , and biotic metabolism (Shailaja et al. 2006; Xue and Warshawsky 2005) . Parent and PAH derivatives are found in complex mixtures in the environment, but modeling the toxicity of mixtures is impractical without an understanding of the potential developmental effects of an individual PAH. The most sensitive life stage to chemical bioactivity is during development when all cellular networks are active. Therefore, development is a critical period of concern for exposure to PAHs, which are known to readily cross the placental barrier (Perera et al. 2004; Zhang et al. 2017) .
Growing evidence associates developmental PAH exposure with adverse effects in early and later life stages.
Increased developmental PAH exposure in humans has been correlated with increased childhood obesity (Rundle et al. 2012) and ADHD rates (Perera et al. 2014) , and decreased IQ (Perera et al. 2006 (Perera et al. , 2009 , height gain, birth weight, birth length, and head circumference in epidemiological studies (Perera et al. 1998) . Aryl hydrocarbon receptor (AhR)-dependent and-independent cardiovascular effects, and oxidative stress are well-studied components of PAH toxicity (Burczynski et al. 1999; Incardona et al. 2004; Incardona et al. 2011; Knecht et al. 2013; Liu et al. 2009; Scott et al. 2011) , and recent studies indicate that persistent neurodevelopmental effects are also important aspects of PAH toxicity (Chen et al. 2012; Crepeaux et al. 2012 Crepeaux et al. , 2013 Incardona et al. 2004 Incardona et al. , 2006 Knecht et al. 2017; Vignet et al. 2014a, b) . In light of this, it is clear that PAHs have distinct bioactivities that cannot be summarized by a single mechanism of action.
Developmental toxicity data and regulations on PAHs have primarily come from studies of benzo [a] pyrene (B[a] P), and to a lesser extent from the other 27 priority PAHs designated by the US Environmental Protection Agency (USEPA) (Ostrowski et al. 1999; USEPA 2010) . The 27 PAHs included in the USEPA's relative potency factor (RPF) approach were selected based on their known carcinogenic potential relative to B[a]P (USEPA 2010), and are limited to parent (unsubstituted) compounds. This means that hundreds of substituted PAHs (e.g., oxygenated, hydroxylated, nitrated, methylated, alkylated, and heterocyclic) are not represented among the developmental toxicity data. Additionally, the RPF PAHs include few high molecular weight PAHs, many of which are known or suspected carcinogens. Therefore, current developmental toxicity data does not effectively capture the structural variability of substituted PAHs, and likely does not capture the complete range of PAH developmental toxicity. Efforts to model PAH toxicity have primarily focused on log K ow as a predictive tool for PAH bioavailability and bioactivity (Billiard et al. 2008; Boese et al. 1999; Mathew et al. 2008; Sabljic 2001) with considerably more success for the former than the latter parameter.
The zebrafish has the distinct advantage of being the only vertebrate model amenable to high throughput testing of a wide range of PAHs for effects on complex end points, and have demonstrated concordance with a variety of mammalian and in vitro models for numerous compounds (Boyd et al. 2016; Volz et al. 2015) . Zebrafish embryos develop externally, rapidly and are transparent, enabling quick assessment of developmental effects, especially organ development and neurobehavioral effects (Dooley and Zon 2000; Peal et al. 2010) . Their small size allows testing of compounds in small volumes, which is ideal for compounds that are difficult to synthesize or obtain in large volumes. Zebrafish are also amenable to molecular and cell culture techniques, making them an ideal model to investigate molecular mechanisms of toxicity. Zebrafish fully support phase I and phase II detoxification pathways by 5 days post fertilization (Goldstone et al. 2010; Kurogi et al. 2013; Le Fol et al. 2017) , allowing them to reveal developmental toxicity that is metabolism dependent. This is particularly useful for evaluating PAH toxicity, which depends, in most cases, on metabolic activation (Incardona et al. 2006; Xue and Warshawsky 2005) . This paper represents the most comprehensive in vivo characterization of PAH and substituted PAH developmental toxicity to date. Morphological and neurobehavioral effects were assessed for 123 commercially available and custom-synthesized PAH standards using the embryonic zebrafish model. The PAHs included 33 parent, 22 nitrated, 17 oxygenated, 19 hydroxylated, 14 methylated, 16 heterocyclic, and 2 aminated (potential metabolites of nitrated PAHs). These structures were selected for broad coverage of environmental and metabolic by-product prevalence. Hydroxy-PAHs were emphasized due to their ready formation as metabolites in fish and humans following PAH exposure, and by fossil fuel combustion and environmental oxidation (Diamanti-Kandarakis et al. 2009; Luderer et al. 2017; Pulster et al. 2017; Simoneit et al. 2007; Wang et al. 2017) . Furthermore, cytochrome P450, family 1, subfamily A (CYP1A) expression patterns were characterized for each compound as an indicator for AhR activation. Results were compared with predicted log K ow values to assess the predictive power of that method.
Methods

Chemicals
Analytical grade standards were obtained from several vendors including: AccuStandard (New Haven, CT, USA), Alfa Aesar (Tewksbury, MA, USA), Chiron Chemicals (Hawthorn, Australia), Combi-Blocks (San Diego, CA, USA), Institute for Reference Materials and Measurements (IRMM) (Geel, Belgium), MRIGlobal (Kansas City, MO, USA), Santa Cruz Biotechnology (SCB) (Dallas, TX, USA), Sigma-Aldrich (Saint Louis, MO, USA), SigmaAldrich Rare Chemical Library (Sigma-Aldrich RCL) (Saint Louis, MO, USA), and Toronto Research Chemicals (TRC) (Toronto, ON, Canada). 3,7-dinitrobenzo[k]fluoranthene and 7-nitrobenzo[k]fluoranthene were synthesized in-house (Jariyasopit et al. 2014a) . In all, standards for 123 PAHs and PAH derivatives were obtained and dissolved in 100% dimethyl sulfoxide (DMSO) to make stock solutions (Table 1 ). 
Zebrafish husbandry
Tropical 5D zebrafish were maintained at the Oregon State University Sinnhuber Aquatic Research Laboratory (SARL, Corvallis, OR), under a 14:10 h light/dark cycle. Fish were raised in densities of ~ 500 fish/50-gallon tank at 28 °C in recirculating filtered water supplemented with Instant Ocean salts. Spawning funnels were placed in tanks the night prior, and the following morning embryos were collected, staged and maintained in an incubator at 28 °C (Kimmel et al. 1995) .
Exposures
The chorions of 4-h post-fertilization (hpf) embryos were enzymatically removed using a custom automated dechorionator and at 6 hpf embryos were placed one per well in round-bottom 96-well plates prefilled with 100 µL of embryo media (EM), using automated embryo placement systems (Mandrell et al. 2012) . A Hewlett Packard D300e chemical dispenser was used to dispense 100% DMSO stocks into two replicate exposure plates. Final DMSO concentrations were normalized to 1% (vol/vol), and gently shaken by the chemical dispenser during dispensing. Plates were sealed with parafilm to minimize evaporation, and shaken overnight at 235 rpm on an orbital shaker at 28 °C to enhance solution uniformity . Embryos were statically exposed until 120 hpf, and kept in a 28 °C incubator for the duration of the exposure. Two test concentration lists were used, depending on the stock concentration and the percentage of DMSO tolerable to developing zebrafish. Exposure concentrations for the 10 and 5 mM stock solutions were: 50, 35.6, 11.2, 5, and 1 µM. Exposure concentrations for the 1 mM stock solutions were: 5, 3.56, 1.12, 0.5, and 0.1 µM. Compounds with high mortality at the 10 mM stock concentrations were rescreened at the 1 mM stock concentrations. Concentrations that had visibly precipitated out of solution by the end of the exposure were excluded from the analysis.
Developmental toxicity screening
At 24 hpf, embryos were assessed for mortality, developmental progression, notochord formation, and spontaneous motion. At 120 hpf, larvae were further assessed for 18 developmental end points: mortality, yolk sac edema, pericardial edema, body axis, trunk length, caudal fin, pectoral fin, pigmentation, somite, eye, snout, jaw, otolith, brain, notochord and circulatory malformations, swim bladder presence and inflation, and touch response. Responses were recorded as a binary absence or presence of an abnormal morphology for each end point. Lowest effect levels (LELs) were calculated for each end point using a binomial test to estimate significance thresholds as previously described (p < 0.05) ).
Embryonic photomotor response
Embryonic photomotor response (EPR) was evaluated in 24 hpf embryos using a custom-built photomotor response assay tool (PRAT) (Noyes et al. 2015) . After chemical exposure, embryos were not exposed to visible light until administration of the EPR test. The test consisted of 30 s of darkness (Background); first pulse of intense light; 9 s of darkness (excitation); second pulse of intense light; 10 s of darkness (refractory). Pixel changes between video frames were recorded to quantify total movement for each embryo across the test. Before analysis, wells with adverse effects (including mortality) observed at 24 hpf were removed. Statistical significance was assessed separately for each interval (background, excitation, and refractory), using a Kolmogerov-Smirnov (KS) test (Bonferroni-corrected p value threshold = 0.05) against the vehicle control animals (Reif et al. 2016) .
Larval photomotor response
Larval photomotor response (LPR) was evaluated in 120 hpf larvae with a light-dark cycle and video tracking software (ViewPoint Life Sciences, Lyon, France). There were a total of four light cycles, each light cycle consisting of 3 min in the light, and 3 min in the dark. Wells with mortality or morbidity were excluded from the data analysis. Statistical significance was quantified using a KS test (p < 0.05) on measured area under the curve, dividing the dark and light cycles into separate bins, and was further constrained by a 50%-fold change threshold of significance for hyper or hypoactivity.
Immunohistochemistry
Immunohistochemistry (IHC) of cytochrome P450, family 1, subfamily A (CYP1A) protein localization was performed as previously described (Mathew et al. 2006) . Briefly, wild type (Tropical 5D) embryos were exposed from 6 to 120 hpf to the highest soluble concentration tested that did not cause significant mortality (Table 1) . Two replicates of eight larvae each were euthanized with tricaine, and fixed overnight in 4% paraformaldehyde at 4 °C. Fixed embryos were permeablized 10 min on ice in 0.005% trypsin, rinsed with PBS + Tween 20 (PBST) and post-fixed in 4% paraformaldehyde for 10 min. Larvae were blocked with 10% normal goat serum (NGS) in PBS + 0.5% Triton X-100 (PBSTx) for 1 h at RT, and incubated overnight in the primary antibody mouse α fish CYP1A monoclonal antibody (BiosenseLaboratories, Bergen, Norway) (1:500) in 1% NGS. Larvae were washed in PBST and incubated for 2 h in secondary antibody (Fluor 594 goat anti-mouse, IgG). Eight embryos per treatment group were assessed by epi-fluorescence microscopy using a Zeiss Axiovert 200M or Keyence BZ-X700 microscope with 10× and 20× objectives and scored for the presence or absence of fluorescence in specific tissues.
Data analysis
All statistical analyses were performed using custom code developed in (R Team 2015) . The heatmap, bar plots, and pie charts were rendered using the ggplot2 package for R (Wickham 2009 ). Hierarchical clustering analyses were conducted using Euclidean distance-based dissimilarity matrices using a "bottom-up" approach. The Venn diagram was created using the online tool "Calculate and draw custom Venn diagrams" created by the Bioinformatics and Evolutionary Genomics group at the University of Gent. The log of the octanol-water partitioning coefficient for each chemical was estimated using EpiSuite™ KOWWIN™ v1.68.
Results
PAH library
A total of 123 PAHs were selected for testing, including parent compounds and a selection of oxygenated, hydroxylated, heterocyclic, nitrated, and aminated derivatives. Selection was primarily based upon obtaining a representative variety of physicochemical properties, to capture the widest possible variety of developmental effects, while also selecting environmentally and metabolically relevant parents and derivatives. Selected compounds contained two to seven fused aromatic rings, which, due to the availability of standards, was weighted slightly towards the smaller, more water soluble structures (Fig. 1) . PAHs with three aromatic rings were the most represented, with a total of 40 tested. Parent PAHs were represented at every ring number, while PAH derivatives were commercially limited to compounds with two to six aromatic rings at the time of procurement.
Developmental toxicity profiles
Embryos were exposed to concentration ranges of each of the 123 PAHs, and were evaluated for adverse morphological effects and neurobehavioral end points across concentrations. The developmental toxicity profiles (Fig. 2) were binned into six distinct groups (1) mortality at low concentrations and few other observed morphological effects, (2) several severe morphological end points at low concentrations, (3) fewer morphological end points primarily at the two highest concentrations tested, (4) no morphological abnormalities, but LPR behavior effects, (5) no morphological abnormalities, but EPR behavior effects, (6) no observed developmental effects. The largest, Group 4, consists only of those with LPR effects, contained 57 PAHs. The next largest, Group 2, severe, varied malformations and high mortality at lower concentrations, contained 25 PAHs. The 18 PAHs of Group 3 affected a handful of non-mortality end points, usually at higher concentrations. The 12 PAHs of Group 1 affected mostly 24 hpf mortality at low concentrations. The 11 PAHs of Group 6 produced no adverse effects. Most compounds with an altered EPR also had other end points affected, but quinoline only had an observed effect on EPR (Group 5). PAHs within a class generally sorted into one or two of the above groups. The majority of PAHs with severe effects (Groups 1 and 2) were oxygenated, hydroxylated, or heterocyclic derivatives. The only parent compounds in these groups were dibenzo[a,l]pyrene and dibenzo [a,c] anthracene. Almost half of the unaffected Group 6 compounds were parent PAHs, the rest a mixture of nitrated and heterocyclic PAHs. Parent compounds were generally less bioactive than their oxygenated, hydroxylated, or nitrated derivatives.
Embryonic photomotor response (EPR)
Of the tested PAHs, 28 resulted in a significant change in EPR in at least one phase (baseline, excitation or refractory) (Fig. 2) . Twelve compounds significantly affected the EPR in the Baseline phase (two hyperactive and ten hypoactive), including one aminated, one methylated, two nitrated, four hydroxylated, and four oxygenated PAHs. 25 PAHs significantly changed EPR in the excitation phase, including two aminated, two methylated, three heterocyclic, three nitrated, five oxygenated, and nine hydroxylated PAHs. Of those, 6 were hyperactive and 19 were hypoactive. Number of Rings Hyperactive compounds were either heterocyclic, hydroxylated or nitrated. Only one compound (dibenzo[a,h]pyrene) significantly altered EPR in the Refractory period, and it had a hypoactive response in this period. This was also the only instance of a parent PAH causing a significant effect in the EPR.
Larval photomotor response (LPR)
A total of 97 PAHs induced a significant change in LPR in at least one phase (light or dark) (Fig. 2) . 54 PAHs significantly changed LPR in the dark phase, including 1 aminated, 4 nitrated, 5 heterocyclic, 7 hydroxylated, 9 oxygenated, 10 methylated, and, 16 parent PAHs. Of those, 34 were hyperactive and 20 were hypoactive. The direction of the LPR effect tended to group based on structure and substitutions. 14 (87%) parent compounds with an effect on the dark phase were hyperactive, as were 5 (71%) hydroxylated compounds, and 6 (60%) of methylated compounds. 2 (50%) nitrated compounds that affected LPR caused hyperactivity in the dark. Heterocyclic and oxygenated compounds mostly caused hypoactivity, with 8 (66%) heterocyclic and oxygenated compounds that affected LPR causing hypoactivity.
81 PAHs significantly altered LPR in the light phase, including 1 aminated, 10 methylated, 10 oxygenated, 11 heterocyclic, 12 nitrated, 13 hydroxylated, and 24 parent PAHs. Of those, 47 were hyperactive and 34 were hypoactive. Similar patterns of direction of effect were seen in the light phase as in the dark phase. 16 (66%) parent, 9 (75%) nitrated, 6 (60%) oxygenated, and 8 (62%) of hydroxylated compounds with effects in the light phase caused hyperactivity. Meanwhile, 9 (82%) heterocyclic compounds and 5 (50%) methylated compounds caused hypoactivity in the light.
CYP1A expression patterns
The highest concentration tested that did not cause significant mortality for each PAH was assessed for CYP1A expression patterns with IHC (Table 1) . Five different tissues expressed CYP1A following PAH exposure (Fig. 3) . Of the 123 PAHs tested, 66 induced CYP1A in at least one tissue type, with most limited to only one tissue (Fig. 4a, b) . The majority of the expression patterns were in the vasculature and the liver (Table 2) . CYP1A was also expressed in the yolk, skin and neuromasts. Vasculature expression was the most common pattern, with 30 PAHs associated with expression of CYP1A in the vasculature. Additionally, 19 compounds induced observable liver expression, 18 induced skin expression, 16 induced yolk expression, and 7 induced neuromast expression. Neuromast expression was seen solely in conjunction with skin expression, and this was the second most common co-expression pattern observed. (Fig. 4b) . Skin expression was observed with PAHs of five or more rings, with the notable exceptions of the four ringnitrated derivatives 6-nitrochrysene and 1,6-dinitropyrene.
Selected comparisons of PAH subgroups
EPA RPF PAHs
18 of the 27 RPF PAHs used by the USEPA were included in our developmental toxicity screen: anthracene, anthanthrene, benzo [a] [a,i] pyrene were the only compounds with no observed morphology effects. All other RPF PAHs fit into one of two categories: LPR effects only (Group 3), or modest non-mortality effects (Group 4). The most common affected end points were pericardial edema, caudal/pectoral fins and pigmentation. Fifteen (83%) tested RPF PAHs were associated with observable CYP1A expression. Six PAHs expressed CYP1A in one tissue type, most commonly in the skin and vasculature (33% each), followed by liver or yolk expression (17% each). Six PAHs (33%) expressed CYP1A in two tissue types, most commonly in the skin (66%), followed by vasculature, neuromasts and liver (33% each). Three RPF PAHs (17%) expressed CYP1A in three tissues, vasculature, skin and neuromasts.
Naphthalene
Naphthalene bioactivity was limited to LPR hyperactivity in both the dark and light phases. The naphthalene derivatives tested included one oxygenated, two nitrated, seven hydroxylated, and eight methylated derivatives. All derivatives except 2,6-dimethylnaphthalene had LPR effects in at least one phase. 2,3-Dihydroxynaphthalene was the only derivative with significant effects on EPR. Four derivatives had effects on mortality or morphology: 1,2-naphthoquinone, 1-hydroxynaphthalene, 2-hydroxynaphthalene and 1,5-dihydroxynaphthalene. The primary end point affected was 5 dpf mortality. The hydroxylated compounds had effects only at the highest concentrations tested, and caused yolk sac and pericardial edemas and pectoral fin malformations, while Fig. 2 Heirarchically clustered heatmap of lowest effect levels for developmental toxicity end points, and neurobehavioral assays (left 5 columns). "Any Effect" and "Any Except Mortality" (right 2 columns) are aggregates of all morphological end points. Darker red color denotes decreased lowest concentration of effect, and higher toxicity. Class of PAH is denoted by color in rightmost column ◂ 1,2 naphthoquinone caused mortality at some of the lowest concentrations tested. Although the majority of naphthalene derivatives did not express CYP1A, some additions of methyl or hydroxyl functional groups resulted in CYP1A expression. 1-Hydroxynaphthalene induced vasculature CYP1A expression, but not 2-hydroxynaphthalene. Both dihydroxynaphthalenes with a hydroxyl group in position 3 induced CYP1A expression, but the position of the second hydroxyl group determined the tissue (vasculature for 2,3, liver for 1,3). 1,5-Dihydroxynaphthalene also resulted in vasculature instead of liver expression. Similar patterns existed for 1,5-dimethylnaphthalene (liver), while methyl groups at the 1,4 positions resulted in vasculature expression.
Anthracene
Anthracene and several derivatives, including a carboxylated derivative, a carbonitrile derivative, three quinones, two nitrated and three methylated derivatives were tested. Anthracene was not bioactive in any of the developmental toxicity assays and not associated with expression of CYP1A, however, all the tested derivatives were bioactive in at least one developmental toxicity assay. The primary effect of anthracene derivatives was on LPR behavior; every derivative except 2-nitroanthracene and 2-ethylanthraquinone affected LPR behavior. The majority of anthracene derivatives did not induce tissue expression of CYP1A. Anthraquinone did not cause morphological effects, but the addition of an ethyl group in the 2 position resulted in effects across 15 end points, including increased mortality, and yolk expression of CYP1A. 1,4-Anthraquinone was the most toxic derivative tested, with increased mortality at concentrations below 10 µM. While inactive in all developmental toxicity assays, 2-nitroanthracene did induce CYP1A expression in the yolk. 9-Anthracene carboxylic acid did not induce CYP1A tissue expression, but 9-anthracene carbonitrile was associated with expression in both liver and yolk. Methylation generally did not affect CYP1A expression, but 9-methylanthracene was associated with CYP1A expression in both vasculature and liver. 
Phenanthrene
Phenanthrene did not induce mortality or morphology changes, EPR effects, or CYP1A tissue expression at the concentrations tested, but did induce hyperactivity in the light period of LPR. One aminated, one methylated, two oxygenated, two nitrated, and four hydroxylated phenanthrenes were screened. Addition of functional groups to phenanthrene resulted in increased bioactivity, except for 3-nitrophenanthrene, which had the same toxicity profile as the parent compound. The developmental effects of the derivatives were primarily characterized by 120 hpf mortality, craniofacial malformations, and yolk sac and pericardial edema. The majority of derivatives did not induce CYP1A expression, however, four phenanthrene derivatives had liver expression, the most common CYP1A pattern amongst the phenanthrenes. In addition to effects on LPR in the light, 3,6-dimethylphenanthrene caused hypoactivity in the EPR, and induced CYP1A expression in the vasculature and the liver.
Pyrene
Unsubstituted pyrene had high LELs (low bioactivity) for several end points, vasculature expression of CYP1A, and significant LPR effects. One aminated, one oxygenated, one hydroxylated and five nitrated derivatives were screened. The mononitrated derivatives had decreased LELs compared to pyrene, but they affected only the cumulative 'any' end points (2-nitropyrene), or the LPR (1-nitropyrene). Compared to unsubstituted pyrene, exposure to pyrene-4,5-dione, 1,6-dinitropyrene, 1,3-dinitropyrene and 1-aminopyrene dramatically increased the developmental toxicity across multiple end points, with significant yolk sac and pericardial edemas, and craniofacial, axial, and fin malformations at lower concentrations. 1-hydroxypyrene and 1,8-dinitropyrene had very similar patterns of effects to pyrene, but those effects were significant at much lower concentrations. Pyrene substitutions altered CYP1A expression patterns, but with no clear trend towards a specific tissue type. In addition to vasculature expression, 1-aminopyrene elicited 
Discussion
In the environment, human and animal exposure to PAHs occur as complex mixtures of parent and substituted structures. A lack of developmental toxicity data for environmentally relevant, substituted PAHs has hindered the estimation of the hazard potential of environmental mixtures (Andersson and Achten 2015). Our results establish a baseline of vertebrate developmental effects associated with exposure to a highly diverse library of 123, mostly substituted, PAHs. We demonstrated that the relationship between structure and toxicity was complex and not predictable by generalized descriptors of physical properties.
No two individual PAH developmental response profiles tested here were identical, and each substituted class ranged from no detectable adverse effects to severely toxic across multiple end points. The developmental toxicity of a substituted PAH structure was not predicted by number of rings, parent compound bioactivity, or log K ow (Fig. S1) . Furthermore, the bioactivity of 18 of the US EPA's 27 priority PAHs grossly under-represented the range of toxic effects that we observed in the 123 PAH libraries, emphasizing the shortcomings of focusing on benzo[a]pyrene and parent PAHs for regulatory purposes. We note that others have recently highlighted similar toxicological limitations with the USEPA-standardized PAH lists (Andersson and Achten 2015; Andreasen 2002) .
Several morphological end points, namely pericardial edema, yolk sac edema, and craniofacial malformations, were common among a majority of the PAHs with developmental effects. This is in accord with vertebrate developmental malformations in response to other strong AhR ligands, the cardiovascular effects of PAHs (Incardona et al. 2004 (Incardona et al. , 2006 Incardona et al. 2011; Knecht et al. 2013 ) and their AhR2-dependent toxicity patterns, including dioxin-like toxicity and CYP1A expression patterns (Goodale et al. 2012; Knecht et al. 2013 ). However, effects not previously associated with developmental PAH exposure were also frequent, including caudal fin, pectoral fin, pigmentation, and touch response abnormalities, demonstrating that solely focusing on cardiovascular effects would ignore other important readouts of hazard potential.
CYP1A expression in the larval zebrafish vasculature and liver is a recognized reporter of AhR2 and AhR1A activation, respectively (Goodale et al. 2012) . Expression of CYP1A in the skin at 120 hpf was previously observed only in response to nitrated PAHs (Chlebowski et al. 2017) , though skin expression of CYP1A has been observed earlier in development in response to other AhR2 ligands (Kim et al. 2013) . In this study, skin expression of CYP1A was only associated with high molecular weight (> MW 250), low solubility (−8.8 < log S < − 6.7) PAHs. A possible explanation for this pattern of CYP1A expression is limited bioavailability, restricting metabolism to the surface of the fish. As a next step, this hypothesis should be tested by examining the relative potency factor of these high MW, low solubility PAHs, measured as transactivation of an AhR2-luciferase reporter (Larsson et al. 2012 (Larsson et al. , 2014 .
Neuromasts are sensory organs in fish and an important part of the lateral line and otic sensory system. These components are analogous to the mammalian inner ear (Ton and Parng 2005) . They are not typically associated with expression of the CYP450 gene family, however, otic expression of CYP1A is known (Incardona et al. 2005) . The ten compounds associated with neuromast CYP1A expression also had altered larval photomotor responses (LPRs). This may be an indirect evidence of disrupted lateral line development, previously associated with abnormal larval photomotor and startle response behaviors (de Esch et al. 2012) .
While yolk syncytial layer expression of CYP1A has been previously observed in zebrafish embryos exposed to PAHs (Chlebowski et al. 2017; Goodale et al. 2015) , little is known about its cause or relevance. CYP450 expression was noted in the yolk syncytial layer in connection with steroidogenesis earlier in development (Hsu et al. 2002) , suggesting that PAH-elicited CYP1A expression is connected to steroid metabolism in the yolk.
An abnormal embryonic photomotor response (EPR) at 24 hpf is generally highly predictive of adverse effects at 120 hpf for a variety of chemical classes (Reif et al. 2016) . Unexpectedly, of the 123 PAHs tested here, only 28 resulted in an abnormal EPR. Of the compounds with significant EPR effects, 68% had morphological effects at 24 hpf, and 75% resulted in morphological effects at 120 hpf, i.e., PAHs with EPR effects comprised only 36% of the structures that elicited morphological effects by 120 hpf. This, combined with the fact that only 28% of the PAHs had morphological effects at 24 h, suggested that the developmental window of bioactivity for most PAHs began after 24 hpf. EPR effects were less likely for PAHs associated with CYP1A expression at 120 hpf (14%) than without (26%). This is consistent with the onset of functional phase I and II metabolism in the developing zebrafish, and conversion of some PAHs to toxic metabolites (Elie et al. 2015; Goldstone et al. 2010; van Grevenynghe et al. 2004) .
The LPR assay revealed bioactivity for several PAHs that did not affect other end points, highlighting the value of behavioral end points in chemical toxicity assessments. Of the 56 PAHs with significant LPR effects, 16 (29%) had no bioactivity in any other assay. The compounds in this group spanned the entirety of the PAH library, and did not have any obvious structural commonalities. LPR effects were equally likely for PAHs with CYP1A expression at 120 hpf (45%) than PAHs without CYP1A expression (47%). Previous work with environmental mixtures was concordant with the hypoactivity observed here, mostly associated with exposure to substituted PAHs (Perrichon et al. 2016) .
The EPR and LPR outcomes suggest that a diverse range of PAH structures can elicit neurobehavioral effects. A higher incidence of LPR effects than EPR effects, and indirect evidence of a post 24 hpf window of bioactivity for most PAHs, indicates that the EPR will likely not be a good predictor of PAH mixture toxicity in future work. Eleven PAHs were not associated with behavioral or morphological effects. This may have resulted from solubility limits in the aqueous exposure medium, where the threshold for morphological or behavioral effects is higher than the top concentrations tested. This might also have been the case for the five dissimilar compounds with no morphological or behavioral effects, but observable CYP1A expression. The CYP1A induction suggests that the compounds interacted with phase I metabolism, while lack of toxicological responses suggests that the five were successfully detoxified or below a concentration threshold for overt toxicity. The remaining six compounds with no associated adverse effects might similarly have been below the toxic threshold. The exceedingly low aqueous solubility of these compounds means that a static bath exposure will likely be unsuccessful for evaluating a toxic threshold and that a direct injection approach should be adopted.
Body burden studies were not performed in parallel with the 123 different exposure experiments, and therefore, the degree to which uptake influenced our results is unknown. There is additional uncertainty in the actual tested concentration because sorptive losses of up to 50% of the analyte have been observed for PAHs in contact with polystyrene . These uncertainties complicate the modeling of PAH toxicity by log K ow , especially because experimental values of log K ow do not exist for most PAHs. Dosimetry modeling is a clear future research need.
Current and proposed methods of modeling PAH toxicity and regulating PAHs in the environment are increasingly recognized as inadequate and overly focused on parent compounds (Andersson and Achten 2015) . Benzo [a] pyrene has been used as a reference for toxicity estimates in many regulatory settings (USEPA 2010). However, in our assays, benzo[a]pyrene was only somewhat representative of the toxicity of other parent compounds, and was far less bioactive than most of the oxygenated and nitrated substitutes. The carcinogenicity and mutagenicity of alkylated, oxygenated and nitrated PAHs can often equal that of the 27 EPA RPF PAHs, and there is ongoing concern that ignoring these derivatives obscure the major drivers of toxicity in environmental risk assessment (Andersson and Achten 2015) . Our data similarly suggested that substituted PAHs are often much more developmentally toxic than their parent compounds.
Although log K ow is generally predictive of bioavailability, it was clearly not predictive of developmental hazard potential for the 123 PAHs here (Fig. S1 ). While general physical descriptors such as log K ow are easy to employ and thus highly tempting to resort to as a means to predict the hazard potential and fate of contamination scenarios, results such as ours demonstrate that a whole animal biosensor approach is both rapid and far more informative.
In conclusion, we characterized the toxicity of 123 parent, oxygenated, hydroxylated, and nitrated PAHs, and identified putative differential AhR dependencies among them. The developmental zebrafish platform enabled a rapid but comprehensive evaluation of the hazard potential of these diverse structures at low cost relative to mammalian models. The results of our somewhat unconventional focus on mostly substituted PAHs, rather than parent USEPA standards, highlight a clear potential for more accurate assessments of environmental and human health hazard. The traditional view of PAHs presenting inherently uniform toxicity, i.e., in the vicinity of B[a]P bioactivity, has already shifted to more refined structure-activity based assessments, and the much needed inclusion of substituted PAH species is well underway. Future studies incorporating a comprehensive approach to body burden will further refine the mechanisms driving the differential toxic effects of individual and mixtures of PAHs.
